CLAIMS

1) A use of pemafibrate or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating atherogenic dyslipidemia in a renally impaired dyslipidemic patient having an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m^2, wherein the medicament is to be administered to the patient in an amount of 0.4mg/day, in combination with moderate to high intensity statin therapy.

2) The use of claim 1, wherein said patient is characterized by increased TG-rich lipoproteins and decreased HDL-C levels.

3) The use of claim 1 or 2, wherein the 0.4 mg per day is the same amount administered to a non-renally impaired patient.

4) A use of pemafibrate or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating artherogenic dyslipidemia in a renally impaired dyslipidemic patient having an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m^2, wherein the medicament is to be administered to the patient in an amount of 0.4mg/day.

5) The use of claim 4, wherein the 0.4 mg/day of pemafibrate or pharmaceutically acceptable salt thereof in the medicament is to be administered in two equal doses of about 0.2 mg.

6) A use of any one of claims 1 to 5, wherein the patient has an eGFR of less than 45 mL/min/1.73 m^2, an eGFR of less than 30 mL/min/1.73 m^2, end stage renal disease, chronic kidney disease, or a TG concentration greater than 150 mg/dL and an HDL-C concentration less than 40 mg/dL, or the patient is characterized by increased TG-rich lipoproteins and decreased HDL-C levels.